IntoCell, Inc.
KKRX:28784016,670.00
KRW
-170.00
(-1.01%)
ISIN
KR7287840003
Return %
Stock
S&P 500
1Y
-63.20
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Tae-Kyo Park
- Full Time Employees
- 43
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Daejeon South Korea
- IPO Date
- May 23, 2025
- Website
- intocell.com
- Similar Companies
- Business
- IntoCell, Inc. is a South Korea-based biotechnology company that develops next-generation antibody-drug conjugate (ADC) platform technologies and targeted oncology therapeutics. The company specializes in the design and synthesis of proprietary linkers and payloads engineered to enhance the stability, drug-to-antibody ratio, and therapeutic window of targeted biopharmaceuticals. IntoCell organizes its offerings into core platform technologies and internal drug development programs: its platform solutions comprise the OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) linker technology, a cleavable linker system engineered to enable stable conjugation and trigger-specific release of phenolic and hydroxyl-containing cytotoxic payloads; the PMAC (Payload-Modified Antibody Conjugation) chemistry, designed to provide site-selective antibody conjugation; and the Nexatecan payload platform, a proprietary series of topoisomerase I inhibitor payloads optimized for enhanced cancer cell cytotoxicity and bystander killing effects; while its therapeutic pipeline includes ITC-6101, a B7-H3-directed antibody-drug conjugate candidate for solid tumor indications; ITC-6102, a HER2-targeted ADC; and multiple discovery-stage ADC programs targeting undisclosed solid tumor and hematological oncology markers. The company provides out-licensing, co-development, and custom ADC synthesis services to multinational biopharmaceutical manufacturers and clinical research organizations. Founded in 2015, IntoCell is headquartered in Daejeon, South Korea, with clinical collaboration and patent licensing activities extending across North America, Europe, and the Asia-Pacific region. In recent operational developments, IntoCell entered into a global collaborative research and licensing agreement with ADC Therapeutics SA to develop novel ADCs utilizing the OHPAS platform technology. The company also secured strategic equity financing from the Samsung Life Science Fund—backed by Samsung C&T, Samsung Biologics, and Samsung Bioepis—to advance next-generation ADC candidate generation. Additionally, IntoCell progressed its public listing on the KOSDAQ market under ticker KRX:287840 to fund IND-enabling studies for its lead drug candidate ITC-6101, expand its international patent portfolio, and scale commercial partnership activities.